A Phase 3 interventional study of Dapagliflozin and Dapagliflozin Placebo in Diabetes, sponsored by AstraZeneca. Completed at 29 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-09.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing dapagliflozin in Diabetes Mellitus — 8 open to participants now, 10 under way, 4 of them phase 3. dapagliflozin · Diabetes Mellitus.
Among the 51 studies testing dapagliflozin in Diabetes Mellitus, this one is the 11th largest by enrollment, is one of 2 that started in 2014, is one of 16 in phase 3, and was the 12th registered.
8,294 studies on the registry are indexed under Diabetes Mellitus; 1,073 are open to participants now.
Browse Diabetes Mellitus studies →8 of the 51 studies testing dapagliflozin in Diabetes Mellitus are open now, in 7 countries. Recruiting first, the newest first:
Boryung Pharmaceutical Co., Ltd · Sites in Korea, Republic of
Ages 19+ · Healthy volunteers
Boryung Pharmaceutical Co., Ltd · Sites in Korea, Republic of
Ages 19+ · Healthy volunteers
University of Colorado, Denver · Sites in United States
Ages 18–80
Kun Hua · Sites in China
Ages 18+
The George Institute · Sites in Australia, Sri Lanka
Ages 18+
By country, each count listing its studies:
dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 650 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 89 take children under 18; 182 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 4 · Phase 3 18 · Phase 4 22
First in 2007; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 477 is above the median of 80 across 6,026 interventional studies indexed under Diabetes Mellitus.
Median enrollment 80 across the 51 interventional studies. Of the 35 that completed or were terminated, 15 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 51 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
122 studies in Diabetes Mellitus by AstraZeneca: none open now, none under way, none of them phase 3. Of 121 finished, 58 (48%) have results posted.
Among the 122 studies in Diabetes Mellitus by AstraZeneca, this one is the 22nd largest by enrollment of the 91 interventional ones that give a count, is one of 8 that started in 2014, is one of 49 in phase 3, and was the 99th registered.
AstraZeneca’s Diabetes Mellitus studies by the year they started, since 2002.
2 of the studies testing dapagliflozin in Diabetes Mellitus that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05174052Phase 3University of OklahomaDapagliflozin in Patients With Atrial Fibrillation (DAPA-AF) | 2027-04 |
| NCT07891234Sherihan AboElyazed Mohamed KhalilEffect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance | 2027-10-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 51 studies testing dapagliflozin in Diabetes Mellitus, from their registry updates:
Among AstraZeneca’s 122 in Diabetes Mellitus:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose is to determine if after 24 weeks of oral daily administration, there will be a greater mean reduction from baseline in glycosylated hemoglobin (HbA1c) achieved with Dapagliflozin 10 mg plus insulin compared to placebo plus insulin in subjects with type 2 diabetes.
Inclusion Criteria:
Inclusion criteria for randomization:
HbA1c ≥ 7.5 and ≤ 10.5% at Day -14
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dapagliflozin 10 mg oral Tablet once daily for 24 weeks + Background Insulin
Drug: Dapagliflozin
Dapagliflozin Placebo 0 mg oral Tablet once daily for 24 weeks + Background Insulin
Drug: Dapagliflozin Placebo
Tablet
Also known as: BMS-512148
Tablet
Adjusted Mean Change in HbA1c From Baseline to Week 24
The adjusted mean change in the percentage of Hemoglobin A1c (HbA1c) from baseline to Week 24 was reported for each arm.
Time frame: Baseline (Day 1) and 24 weeks
Adjusted Mean Change in Fasting Plasma Glucose (FPG) From Baseline to Week 24
The adjusted mean change from baseline to 24 weeks in Fasting Plasma Glucose (FPG) was reported for each arm in milligrams per deciliter (mg/dL).
Time frame: Baseline (Day 1) and 24 weeks
Adjusted Mean Change in Body Weight From Baseline to Week 24
Adjusted mean change in body weight from baseline to week 24 was reported for each arm in kilograms (kg).
Time frame: Baseline (Day 1) and 24 weeks
Adjusted Mean Change in Absolute Calculated Mean Total Daily Dose of Insulin (TDDI) From Baseline to Week 24
The adjusted mean change in absolute calculated mean Total Daily Dose of Insulin (TDDI) from baseline to week 24 was reported for each arm in International Units (IU).
Time frame: Baseline (Day 1) and 24 weeks
| Milestone | Placebo | Dapagliflozin |
|---|---|---|
| Started | 133 | 139 |
| Completed | 124 | 134 |
| Not completed | 9 | 5 |
| Withdrew: Adverse event | 6 | 3 |
| Withdrew: Subject request to discontinue treatment | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Other | 1 | 1 |
| Milestone | Placebo | Dapagliflozin |
|---|---|---|
| Started | 129 | 139 |
| Completed | 125 | 135 |
| Not completed | 4 | 4 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Subjects not reporting status | 1 | 2 |
The adjusted mean change in the percentage of Hemoglobin A1c (HbA1c) from baseline to Week 24 was reported for each arm.
| percentage of hemoglobin | Placebo | Dapagliflozin |
|---|---|---|
| Adjusted Mean Change in HbA1c From Baseline to Week 24 | 0.03 ± 0.0707 | -0.87 ± 0.0666 |
The adjusted mean change from baseline to 24 weeks in Fasting Plasma Glucose (FPG) was reported for each arm in milligrams per deciliter (mg/dL).
| mg/dL | Placebo | Dapagliflozin |
|---|---|---|
| Adjusted Mean Change in Fasting Plasma Glucose (FPG) From Baseline to Week 24 | 0.07 ± 3.3803 | -30.62 ± 3.1314 |
Adjusted mean change in body weight from baseline to week 24 was reported for each arm in kilograms (kg).
| kilograms | Placebo | Dapagliflozin |
|---|---|---|
| Adjusted Mean Change in Body Weight From Baseline to Week 24 | 0.37 ± 0.2224 | -1.00 ± 0.2103 |
The adjusted mean change in absolute calculated mean Total Daily Dose of Insulin (TDDI) from baseline to week 24 was reported for each arm in International Units (IU).
| International Units (IU) | Placebo | Dapagliflozin |
|---|---|---|
| Adjusted Mean Change in Absolute Calculated Mean Total Daily Dose of Insulin (TDDI) From Baseline to Week 24 | 0.74 ± 0.3723 | -0.70 ± 0.3592 |
Collected over 24 week treatment period + 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dapagliflozin | — | 8/139 (5.8%) | 61/139 (43.9%) |
| Placebo | — | 18/133 (13.5%) | 61/133 (45.9%) |
| Event | Dapagliflozin | Placebo |
|---|---|---|
| FOOT DEFORMITYMusculoskeletal and connective tissue disorders | 0/139 | 2/133 |
| ACUTE MYOCARDIAL INFARCTIONCardiac disorders | 0/139 | 1/133 |
| ANGINA PECTORISCardiac disorders | 0/139 | 1/133 |
| MYOCARDIAL BRIDGINGCongenital, familial and genetic disorders | 0/139 | 1/133 |
| CATARACTEye disorders | 0/139 | 1/133 |
| UVEITISEye disorders | 0/139 | 1/133 |
| NEUROSYPHILISInfections and infestations | 0/139 | 1/133 |
| HUMERUS FRACTUREInjury, poisoning and procedural complications | 0/139 | 1/133 |
| HYPERGLYCAEMIAMetabolism and nutrition disorders | 0/139 | 1/133 |
| PERIARTHRITISMusculoskeletal and connective tissue disorders | 0/139 | 1/133 |
| Event | Dapagliflozin | Placebo |
|---|---|---|
| HYPERLIPIDAEMIAMetabolism and nutrition disorders | 31/139 | 31/133 |
| DYSLIPIDAEMIAMetabolism and nutrition disorders | 9/139 | 12/133 |
| HYPERURICAEMIAMetabolism and nutrition disorders | 12/139 | 12/133 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 8/139 | 9/133 |
| NASOPHARYNGITISInfections and infestations | 5/139 | 7/133 |
| URINARY TRACT INFECTIONInfections and infestations | 5/139 | 7/133 |
All Randomized Participants
| Age, Categorical(Participants) | Placebo | Dapagliflozin | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 97 | 117 | 214 |
| >=65 years | 36 | 22 | 58 |
| Age, Continuous(years) | Placebo | Dapagliflozin | Total |
|---|---|---|---|
| Mean | 58.6 ± 8.91 | 56.5 ± 8.39 | 57.5 ± 8.70 |
| Sex: Female, Male(Participants) | Placebo | Dapagliflozin | Total |
|---|---|---|---|
| Female | 69 | 73 | 142 |
| Male | 64 | 66 | 130 |
Ran from Mar 2014 to primary completion in Jan 2016, 21 months.
Results were first posted in Mar 2017, 1 year 1 month after primary completion.
Of 167 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 23. This study's 21 months is above that.
Counting every sponsor, half of 230 studies reached it within 19 months; a quarter within 13 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dapagliflozin